Clinical Trials News

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squamous or non-squamous non-small cell lung cancer.

The Checkmate 384 study will investigate whether or not progression-free survival at 6 months and at 1 year after receiving twice the dose of nivolumab half as frequently is inferior to nivolumab 240 mg every 2 weeks.

Read the Patient Newsletter: http://lcfamerica.org/wp-content/uploads/2017/02/Issue-49-for-January-TOTR-Patient-Newsletter.pdf